On February 23, 2026, during Rare Disease Week, the FDA released draft guidance that could fundamentally change how ultra-rare diseases are treated. The document, titled 'Considerations for the Use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause,' describes a new pathway for approving one-of-a-kind treatments when traditional clinical trials are not feasible.
The Baby Who Changed the Conversation
The framework did not come out of nowhere. It was partly inspired by the case of an infant known as KJ, who was born with carbamoyl phosphate synthetase 1 (CPS1) deficiency, a condition that affects roughly 1 in 1.3 million people according to medical literature. CPS1 deficiency prevents the liver from processing ammonia, a toxic byproduct of protein metabolism. Without treatment, ammonia builds up to dangerous levels in the blood and brain, causing seizures, brain damage, and often death.
A team at Children's Hospital of Philadelphia and the University of Pennsylvania, led by Dr. Rebecca Ahrens-Nicklas and Dr. Kiran Musunuru, developed a personalized CRISPR base-editing therapy targeting KJ's specific genetic mutation (Q335X). According to CHOP, from diagnosis to first dose took about six months. KJ received three doses beginning in late February 2025, delivered via lipid nanoparticles to the liver.
The results were encouraging. KJ tolerated the treatment without serious side effects, was able to eat more protein, needed less ammonia-lowering medication, and recovered from a childhood illness without the dangerous ammonia spikes that would have been expected. As of the most recent reports, KJ is growing and developing.
What the Framework Actually Changes
Under the traditional FDA approval process, drug developers typically need two adequate and well-controlled clinical studies to demonstrate that a treatment works. For a disease that affects 50 people on the planet, that standard is essentially impossible to meet.
The plausible mechanism framework allows approval based on a well-characterized scientific basis for how a therapy works against a clearly defined molecular or cellular abnormality. In practical terms, this means a developer can demonstrate that a treatment targets the root cause of a genetic disease, show evidence that it engages the biological target, and rely on natural history data from untreated patients as a comparison, without needing a traditional randomized controlled trial.
The framework explicitly covers genome editing therapies (like the CRISPR approach used for KJ), antisense oligonucleotides, gene therapy delivered through lipid nanoparticles, and potentially other modalities that directly address known genetic causes. The FDA indicated the framework is intentionally broad and may expand over time.
Not Everyone Is Convinced
The response from the rare disease community has been mixed. Patient advocacy groups broadly welcomed the intent. For families who have watched children decline while waiting for treatments to clear a regulatory process designed for common diseases, any move toward faster approval pathways is significant.
But some experts have raised concerns. Paul Kim, an advisor to the National Organization for Rare Disorders, called earlier iterations of the framework 'all wrapper and no gift,' suggesting the guidance lacks specifics on implementation. Others worry that lowering the evidence bar, even for ultra-rare diseases, could lead to approvals based on insufficient data. The question of who pays for individualized therapies that may cost millions per patient remains open.
Industry observers have also flagged the challenge of regulatory unpredictability. Several companies that relied on FDA guidance during development have seen the agency reverse course at the approval stage, a pattern that has eroded trust. Whether this framework holds up in practice, or shifts as leadership changes, is something the rare disease community will be watching closely.
Why This Matters
The plausible mechanism framework is not a silver bullet. It does not solve the funding challenges, the manufacturing complexity, or the access barriers that make individualized medicine difficult. But it does remove one of the biggest structural obstacles: the requirement to generate evidence that is physically impossible to generate for diseases that affect single-digit patient populations.
For the thousands of families living with ultra-rare genetic conditions, this framework represents something that has been missing: a formal acknowledgment from the FDA that the traditional evidence standard is not appropriate for every disease, and that patients with the rarest conditions deserve a realistic path to treatment. The public comment period is open until April 27, 2026, and the rare disease community is paying close attention to what comes next.
“The cost of inaction is not zero. For progressive, life-threatening conditions with no alternatives, waiting for perfect evidence means watching patients decline.”